As shown in Table 2, patients with stage III-IV tumors, a higher rate of lymph node metastasis, and TNM stages III-IV had significantly higher expressions of FLJ10540 or osteopontin compared with patients with stage I-II tumors (p<0. Here, SPP1 is linked to metastatic malignant neoplasm in the lymph nodes.